Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Jayanthan, Aarthi ^a   Bernoux, Delphine ^a   Bose, Pinaki ^b   Riabowol, Karl ^b   Narendran, Aru ^a  

^a ALBERTA CHILDREN'S HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM ATYPICAL TERATOID RHABDOID TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; PARACRINE SIGNALING; PEDIATRICS; RHABDOID TUMOR;

EID: 84855182679     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-44     Document Type: Article

References (46)

1. Bikowska B, Grajkowska W, Jozwiak J. Atypical teratoid/rhabdoid tumor: short clinical description and insight into possible mechanism of the disease. Eur J Neurol 2011, 18:813-818. 10.1111/j.1468-1331.2010.03277.x, 21159066.
2. Biegel JA. Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 2006, 20:E11. 10.3171/foc.2006.20.4.6, 16819809.
3. Dufour C, Beaugrand A, Le Deley MC, Bourdeaut F, André N, Leblond P, Bertozzi AI, Frappaz D, Rialland X, Fouyssac F, Edan C, Grill J, Quidot M, Varlet P. Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: A multicenter study. Cancer 2011, Electronically published ahead of print.
4. Bouvier C, De Paula AM, Fernandez C, Quilichini B, Scavarda D, Gentet JC, Figarella-Branger D. Atypical teratoid/rhabdoid tumor: 7-year event-free survival with gross total resection and radiotherapy in a 7-year-old boy. Childs Nerv Syst 2008, 24:143-147.
5. Guidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W, Smith TW, Imbalzano AN, Jones SN. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 2001, 21:3598-3603. 10.1128/MCB.21.10.3598-3603.2001, 100281, 11313485.
6. Foster KS, McCrary WJ, Ross JS, Wright CF. Members of the hSWI/SNF chromatin remodeling complex associate with and are phosphorylated by protein kinase B/Akt. Oncogene 2006, 25:4605-4612. 10.1038/sj.onc.1209496, 16568092.
7. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Izumi T, Ohta S, Taguchi T, Suita S, Tsuneyoshi M. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR. J Cancer Res Clin Oncol 2007, 133:817-824. 10.1007/s00432-007-0223-z, 17486366.
8. Albanese P, Belin MF, Delattre O. The tumor suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells. Eur J Cancer 2006, 42:2326-2334. 10.1016/j.ejca.2006.03.028, 16908131.
9. Narendran A, Coppes L, Jayanthan A, Coppes M, Teja B, Bernoux D, George D, Strother D. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. J Neurooncol 2008, 90:171-180. 10.1007/s11060-008-9653-y, 18651103.
10. D'cunja J, Shalaby T, Rivera P, von Büren A, Patti R, Heppner FL, Arcaro A, Rorke-Adams LB, Phillips PC, Grotzer MA. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur J Cancer 2007, 43:1581-1589. 10.1016/j.ejca.2007.03.003, 17446062.
11. Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, Jackson SP, Schoenwaelder SM, Delattre O, Grotzer MA, Fischer B. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J 2007, 406:57-66. 10.1042/BJ20070309, 1948991, 17506723.
12. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008, 15:422-432. 10.2174/092986708783503212, 18288997.
13. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009, 23:377-389. 10.2165/11318860-000000000-00000, 19894779.
14. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects. Curr Drug Metab 2009, 10:470-481. 10.2174/138920009788897975, 19689244.
15. Feun L, Savaraj N. Topoisomerase I inhibitors for the treatment of brain tumors. Expert Rev Anticancer Ther 2008, 8:707-716. 10.1586/14737140.8.5.707, 18471044.
16. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446. 10.1158/0008-5472.CAN-09-1947, 20068163.
17. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005, 5:297-309. 10.1038/nrc1588, 15803156.
18. Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D, Rousseau D, Berard E, Dreano M, Peyron JF. Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 2008, 98:335-344. 10.1038/sj.bjc.6604082, 2361441, 18182997.
19. Schiappacassi M, Lovat F, Canzonieri V, Belletti B, Berton S, Di Stefano D, Vecchione A, Colombatti A, Baldassarre G. p27Kip1 expression inhibits glioblastoma growth, invasion and tumor-induced neoangiogenesis. Mol Cancer Ther 2008, 7:1164-1175. 10.1158/1535-7163.MCT-07-2154, 18483304.
20. Strother D. Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Ther 2005, 5:907-915. 10.1586/14737140.5.5.907, 16221059.
21. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajjar A. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005, 23:1491-1499. 10.1200/JCO.2005.05.187, 15735125.
22. Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M. High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 2008, 112:1345-1353. 10.1002/cncr.23305, 18224664.
23. Gidwani P, Levy A, Goodrich J, Weidenheim K, Kolb EA. Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system. J Neurooncol 2008, 88:211-215. 10.1007/s11060-008-9553-1, 18317689.
24. Squire SE, Chan MD, Marcus KJ. Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy. J Neurooncol 2007, 81:97-111.
25. Chen YW, Wong TT, Ho DM, Huang PI, Chang KP, Shiau CY, Yen SH. Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). Int J Radiat Oncol Biol Phys 2006, 64:1038-1043. 10.1016/j.ijrobp.2005.10.001, 16406394.
26. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 2009, 27:385-389. 2645855, 19064966.
27. Ogino S, Kubo S, Abdul-Karim FW, Cohen ML. Comparative immunohistochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors. Pediatr Dev Pathol 2001, 4:23-31. 10.1007/s100240010112, 11200487.
28. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007, 12:191-200. 10.1634/theoncologist.12-2-191, 17296815.
29. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
30. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005, 24:6861-6869. 10.1038/sj.onc.1208841, 16007148.
31. Warr MR, Shore GC. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008, 8:138-147. 10.2174/156652408783769580, 18336294.
32. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, Tye G, Kirschbaum M, Jove R. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 2008, 7:3519-3526. 10.1158/1535-7163.MCT-08-0138, 2592687, 19001435.
33. Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 2010, 8:35-45. 10.1158/1541-7786.MCR-09-0220, 2808420, 20053726.
34. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 51:42-48. 10.1002/pbc.21535, 18293383.
35. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995, 36:393-403. 10.1007/BF00686188, 7634381.
36. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 2001, 7:32-37.
37. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7:1152-1160. 10.1016/S1474-4422(08)70260-6, 19007739.
38. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 2009, 11:80-91. 2718962, 18784279.
39. Calvo E, Cortes J, Rodriguez J, Fernandez-Hidalgo O, Rebollo J, Martin-Algarra S, Garcia-Foncillas J, Martinez-Monge R, de Irala J, Brugarolos A. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a Phase II study. Clin Colorectal Cancer 2002, 2:104-110. 10.3816/CCC.2002.n.016, 12453325.
40. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002, 13:1841-1851. 10.1093/annonc/mdf337, 12453851.
41. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
42. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 2004, 10:3333-3341. 10.1158/1078-0432.CCR-03-0366, 15161687.
43. Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D, Rousseau D, Berard E, Dreano M, Peyron JF. Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 2008, 98:335-344. 10.1038/sj.bjc.6604082, 2361441, 18182997.
44. Echeverria V, Burgess S, Gamble-George J, Zeitlin R, Lin X, Cao C, Arendash GW. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 2009, 162:1220-1231. 10.1016/j.neuroscience.2009.05.019, 19447162.
45. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008, 123:2031-2040. 10.1002/ijc.23732, 2574811, 18697197.
46. Han X, Feng X, Rattner JB, Smith H, Bose P, Suzuki K, Soliman MA, Scott MS, Burke BE, Riabowol K. Tethering of the ING1 protein to Lamin A is required for ING1 function in apoptosis. Nat Cell Biol 2008, 10:1333-1340. 10.1038/ncb1792, 18836436.